Brand and Other Names:Actimmune
- Classes: Biological Response Modifiers
Dosing & Uses
Dosage Forms & Strengths
- 100mcg/0.5mL (single-dose vial)
- 50mcg = 1 million units/m²
Chronic Granulomatous Disease
Indicated to reduce frequency and severity of infections associated with chronic granulomatous disease
BSA ≤0.5 m²: 1.5 mcg/kg SC 3 times/week
Indicated to delay time to progression for severe malignant osteopetrosis
BSA ≤0.5 m²: 1.5 mcg/kg SC 3 times/week
Renal cell carcinoma
- Horizon Pharma Ireland Limited; Adelaide Chambers; Dublin 8; IRELAND
Optimum sites are right and left deltoid, anterior thigh
If severe reactions occur, reduce dose by 50 percent or discontinue therapy until the adverse reaction abates
CBC, blood chemistries, urinalysis: q3month
Serious - Use Alternative
Significant - Monitor Closely
Injection site erythema/tenderness (14%)
Hypersensitivity to interferon gamma or E. coli-derived products
Potential for hepatotoxicity
If severe reactions occur, decrease dose 50% or withhold until side effects subside
Caution in cardiovascular disease; pre-existing cardiac conditions may be exacerbated
Reduce dose or discontinue if decreased mental status, gait disturbance, dizziness occur
Monitor for neutropenia and thrombocytopenia particularly when administering in combination with other potentially myelosuppressive agents
Reduce dose or discontinue to reverse severe elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT); monitor liver function monthly in patients <1 year old
If serious hypersensitivity reactions occur, discontinue and institute appropriate medical therapy
Monitor renal function regularly when administering therapy to patients with severe renal insufficiency
Refrigerate vials-do not freeze or shake
The stopper of the glass vial contains natural rubber (a derivative of latex) which may cause allergic reactions
May cause flu-like symptoms
No preservatives-discard unused portions
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Not known whether excreted in breast milk, discontinue drug or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Recombinant human interferon gamma-1b, cytokine that confers greater resistance to microbial pathogens and regulates immune processes
Absorption: 89% (SC, IM)
Half-life: 38 min (IV); 3 hr (IM); 5.9 hr (SC)
Peak plasma time: 4 hr (IM); 7 hr (SC)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs